EP3310356A4 - Compositions for the improvement of distance vision and the treatment of refractive errors of the eye - Google Patents

Compositions for the improvement of distance vision and the treatment of refractive errors of the eye Download PDF

Info

Publication number
EP3310356A4
EP3310356A4 EP16812174.7A EP16812174A EP3310356A4 EP 3310356 A4 EP3310356 A4 EP 3310356A4 EP 16812174 A EP16812174 A EP 16812174A EP 3310356 A4 EP3310356 A4 EP 3310356A4
Authority
EP
European Patent Office
Prior art keywords
eye
compositions
improvement
treatment
distance vision
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16812174.7A
Other languages
German (de)
French (fr)
Other versions
EP3310356A1 (en
Inventor
Gerald Horn
Lee NORDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lenz Therapeutics Operations Inc
Original Assignee
Presbyopia Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/742,903 external-priority patent/US9320709B2/en
Priority claimed from US14/742,921 external-priority patent/US9314427B2/en
Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc
Publication of EP3310356A1 publication Critical patent/EP3310356A1/en
Publication of EP3310356A4 publication Critical patent/EP3310356A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP16812174.7A 2015-06-18 2016-06-09 Compositions for the improvement of distance vision and the treatment of refractive errors of the eye Pending EP3310356A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/742,903 US9320709B2 (en) 2013-08-28 2015-06-18 Storage stable compositions and methods for the treatment of refractive errors of the eye
US14/742,921 US9314427B2 (en) 2013-08-28 2015-06-18 Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
PCT/US2016/036692 WO2016205069A1 (en) 2015-06-18 2016-06-09 Compositions for the improvement of distance vision and the treatment of refractive errors of the eye

Publications (2)

Publication Number Publication Date
EP3310356A1 EP3310356A1 (en) 2018-04-25
EP3310356A4 true EP3310356A4 (en) 2018-12-05

Family

ID=57545598

Family Applications (3)

Application Number Title Priority Date Filing Date
EP16812174.7A Pending EP3310356A4 (en) 2015-06-18 2016-06-09 Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
EP16812173.9A Pending EP3310336A4 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye
EP24172129.9A Pending EP4385521A2 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP16812173.9A Pending EP3310336A4 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye
EP24172129.9A Pending EP4385521A2 (en) 2015-06-18 2016-06-09 Storage stable compositions and methods for the treatment of refractive errors of the eye

Country Status (9)

Country Link
EP (3) EP3310356A4 (en)
JP (3) JP6838712B2 (en)
KR (4) KR102598047B1 (en)
CN (3) CN107920984A (en)
AU (2) AU2016280616B2 (en)
CA (2) CA2987783A1 (en)
HK (1) HK1254338A1 (en)
MX (2) MX2017016517A (en)
WO (2) WO2016205068A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987783A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Storage stable compositions and methods for the treatment of refractive errors of the eye
JP7016880B2 (en) * 2017-03-23 2022-02-07 シンガポール ヘルス サービシーズ ピーティーイー リミテッド Myopia prophylaxis, myopia treatment and / or myopia progression inhibitor containing tiotropium as an active ingredient
CN110621298B (en) * 2017-05-11 2022-12-20 维卢玛有限公司 Atropine pharmaceutical composition
US10836760B2 (en) * 2018-10-10 2020-11-17 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
WO2020117637A1 (en) * 2018-12-05 2020-06-11 Presbyopia Therapies Llc Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
KR20230131822A (en) * 2020-10-13 2023-09-14 렌즈 테라퓨틱스 인코포레이티드 Compositions and methods for storage stable eye drops
CR20230190A (en) * 2020-11-02 2023-09-06 Visus Therapeutics Inc Degradant compound in a medicament
PE20241644A1 (en) * 2021-03-16 2024-08-09 Vyluma Inc MULTI-DOSE PACKAGING FOR OPHTHALMIC COMPOSITIONS
KR20220154509A (en) 2021-05-13 2022-11-22 전연우 A medicine bottle that tells you when to take it and allows you to take it out comfortably
TW202333700A (en) * 2021-12-16 2023-09-01 美商倫茨治療公司 Compositions and methods for the treatment of eye conditions
KR20230126461A (en) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 A structure of polymer hyaluronic acid, manufacturing method thereof and cosmetic composition comprising the same
KR20230126522A (en) * 2022-02-23 2023-08-30 주식회사 스카이테라퓨틱스 A structure of polymer hyaluronic acid, manufacturing method thereof and eye drop composition comprising the same
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
CN117982412B (en) * 2024-02-04 2024-09-17 济川(上海)医学科技有限公司 Acaclidinium ophthalmic composition, pharmaceutical preparation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015031186A1 (en) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions and methods for the treatment of presbyopia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US6291466B1 (en) 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
JP2003513951A (en) * 1999-11-09 2003-04-15 アルコン，インコーポレイテッド Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
ITMI20010708A1 (en) * 2001-04-03 2002-10-03 Alessandro Randazzo PHARMACOLOGICAL TREATMENT OF NIGHT BLINDS AND GHOST IMAGES WITH DILUTED PARASYMPATHOMYMETICS ACECLIDINE / PILOCARPINE AFTER INTER
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US7830573B2 (en) 2005-11-03 2010-11-09 Stamper Technologies, Inc. Method and system for producing multiple images in a single image plane using diffraction
EP1938839B1 (en) 2006-12-18 2009-08-19 Jorge Luis Benozzi Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
WO2009072007A2 (en) * 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
CN104093404B (en) 2011-09-20 2016-12-07 阿勒根公司 For treating presbyopia, slight hypermetropia and the compositions of irregular astigmatism and method
KR20140103099A (en) * 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 Prevention and treatment of ocular conditions
DE102011121770A1 (en) 2011-12-21 2013-06-27 Oerlikon Trading Ag, Trübbach Homogeneous HIPIMS coating process
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US9573840B2 (en) * 2013-08-27 2017-02-21 Corning Incorporated Antimony-free glass, antimony-free frit and a glass package that is hermetically sealed with the frit
CA2987783A1 (en) * 2015-06-18 2016-12-22 Presbyopia Therapies, LLC Storage stable compositions and methods for the treatment of refractive errors of the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015031186A1 (en) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
KR20230085217A (en) 2023-06-13
CN107920984A (en) 2018-04-17
CA2987783A1 (en) 2016-12-22
JP6835747B2 (en) 2021-02-24
KR20180014825A (en) 2018-02-09
KR102667598B1 (en) 2024-05-20
KR102598047B1 (en) 2023-11-06
EP3310336A4 (en) 2018-12-05
JP2021035954A (en) 2021-03-04
MX2017016518A (en) 2018-05-28
AU2016280616B2 (en) 2020-10-22
CA2987787C (en) 2023-06-27
CA2987787A1 (en) 2016-12-22
JP7026189B2 (en) 2022-02-25
KR20230156161A (en) 2023-11-13
CN116808032A (en) 2023-09-29
JP2018517738A (en) 2018-07-05
CN107847492B (en) 2021-05-25
EP3310336A1 (en) 2018-04-25
KR20180014824A (en) 2018-02-09
HK1254338A1 (en) 2019-07-19
CN107847492A (en) 2018-03-27
JP6838712B2 (en) 2021-03-03
EP4385521A2 (en) 2024-06-19
WO2016205069A1 (en) 2016-12-22
AU2016280616A1 (en) 2017-12-14
BR112017025726A2 (en) 2018-08-14
WO2016205068A1 (en) 2016-12-22
JP2018517740A (en) 2018-07-05
AU2016280615A1 (en) 2017-12-14
AU2016280615B2 (en) 2020-10-01
MX2017016517A (en) 2018-05-28
BR112017025722A2 (en) 2018-08-07
EP3310356A1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
EP3310356A4 (en) Compositions for the improvement of distance vision and the treatment of refractive errors of the eye
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3390634A4 (en) Compositions and methods for treatment of eye diseases
GB201913962D0 (en) Ophthalmic drug compositions
EP3160471A4 (en) Ophthalmic composition
EP3291765A4 (en) Methods of delivering an agent to the eye
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3472317A4 (en) Compositions and methods for reducing ocular neovascularization
EP3500255A4 (en) Ophthalmic pharmaceutical compositions and uses relating thereto
EP3265096A4 (en) Ophthalmic compositions and methods of use therefor
EP3164058A4 (en) Systems and methods for alignment of the eye for ocular imaging
EP3452075A4 (en) Ophthalmic pharmaceutical composition
EP3672587A4 (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
EP3352749A4 (en) Compounds and compositions for the treatment of ocular disorders
EP3397995A4 (en) Ophthalmic lens
GB201619525D0 (en) Ophthalmic composition
EP3481411A4 (en) Treatment for glaucoma and other eye diseases
GB2541840B (en) Ophthalmic composition for the treatment of ocular infection
EP3185825A4 (en) Surgical eye shield
EP3672598A4 (en) Ocular pharmaceutical compositions
IL282504A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
EP3216451A4 (en) Ophthalmic aqueous composition
EP3452015A4 (en) Compositions and methods for treatment of inflammation or infection of the eye
PL3072503T3 (en) Ophthalmic composition for the corneal protection

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20181023BHEP

Ipc: A61P 27/10 20060101ALI20181023BHEP

Ipc: A61K 31/439 20060101AFI20181023BHEP

Ipc: A61K 9/08 20060101ALI20181023BHEP

Ipc: A61K 47/26 20060101ALI20181023BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PRESBYOPIA THERAPIES, INC.

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LENZ THERAPEUTICS, INC.

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LENZ THERAPEUTICS OPERATIONS, INC.